IRIS
IACOBELLI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.048
EU - Europa 5.243
AS - Asia 4.746
SA - Sud America 639
AF - Africa 46
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 4
Totale 17.739
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.944
SG - Singapore 2.039
CN - Cina 1.461
UA - Ucraina 968
IE - Irlanda 849
GB - Regno Unito 739
SE - Svezia 634
TR - Turchia 599
FR - Francia 588
BR - Brasile 553
IT - Italia 513
DE - Germania 356
IN - India 247
FI - Finlandia 218
RU - Federazione Russa 168
VN - Vietnam 168
CA - Canada 58
PL - Polonia 48
BE - Belgio 44
HK - Hong Kong 38
JP - Giappone 32
KR - Corea 32
MX - Messico 31
AR - Argentina 30
IQ - Iraq 24
BD - Bangladesh 22
CZ - Repubblica Ceca 22
ES - Italia 21
ZA - Sudafrica 21
NL - Olanda 19
AT - Austria 18
LT - Lituania 13
UZ - Uzbekistan 13
VE - Venezuela 13
EC - Ecuador 12
IR - Iran 12
EU - Europa 11
IL - Israele 10
ID - Indonesia 9
AE - Emirati Arabi Uniti 7
CO - Colombia 7
UY - Uruguay 7
CH - Svizzera 6
EG - Egitto 5
KE - Kenya 5
PE - Perù 5
PK - Pakistan 5
PY - Paraguay 5
SA - Arabia Saudita 5
AL - Albania 4
AZ - Azerbaigian 4
CL - Cile 4
DO - Repubblica Dominicana 4
GR - Grecia 4
MA - Marocco 4
TN - Tunisia 4
AU - Australia 3
JO - Giordania 3
NP - Nepal 3
PT - Portogallo 3
RO - Romania 3
RS - Serbia 3
SN - Senegal 3
TW - Taiwan 3
BO - Bolivia 2
DZ - Algeria 2
HN - Honduras 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BY - Bielorussia 1
CR - Costa Rica 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 17.739
Salva come PNG Salva come JPEG
Città #
Singapore 1.509
Jacksonville 1.062
Chandler 1.053
Dublin 843
Southend 558
Dallas 400
Princeton 385
Beijing 339
Izmir 329
Nanjing 307
Ashburn 305
Los Angeles 217
Santa Clara 207
The Dalles 189
Cambridge 177
Wilmington 177
Tongling 140
Boardman 134
Ann Arbor 127
Buffalo 111
Nanchang 111
New York 110
Dearborn 105
Altamura 91
Chieti 63
Munich 62
Woodbridge 62
São Paulo 56
Hebei 53
Ho Chi Minh City 51
Shenyang 50
Tianjin 46
Brussels 43
Council Bluffs 43
Pescara 43
Kunming 42
Redondo Beach 37
Hong Kong 36
Brooklyn 33
Houston 33
Seoul 30
Jiaxing 29
Hanoi 28
Tokyo 28
Stockholm 27
Warsaw 27
Boston 26
Norwalk 26
Denver 25
Dong Ket 24
London 24
Hangzhou 23
Hefei 23
Atlanta 22
Changsha 22
Chennai 22
Chicago 22
Nuremberg 22
Poplar 22
Helsinki 20
Falls Church 19
Kocaeli 19
Montreal 19
Grevenbroich 18
Turku 18
Brno 17
Montesilvano 17
Orem 17
Collecorvino 16
Johannesburg 16
Manchester 16
Washington 16
Phoenix 15
Rome 15
San Mateo 15
Jinan 14
Kraków 14
Lanzhou 14
Moscow 14
Orange 14
San Francisco 14
Augusta 13
Hyderabad 13
Leawood 13
Rio de Janeiro 13
Tashkent 13
Belo Horizonte 12
Auburn Hills 11
Campinas 11
Milan 11
Ankara 10
Guangzhou 10
Lappeenranta 10
Salvador 10
Seattle 10
Toronto 10
Changchun 9
Düsseldorf 9
Mexico City 9
Mumbai 9
Totale 10.774
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 176
90K (Mac-2 BP) in human milk 161
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 158
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 149
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 148
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 147
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 147
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 144
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 141
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 140
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 137
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 135
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 134
New Targets for Therapy in Pancreatic Cancer 134
Prognostic relevance of LGALS3BP in human colorectal carcinoma 133
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 132
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 132
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. 131
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 130
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 129
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 127
ERBB3 BINDING ANTIBODY 127
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 126
Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants 126
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 123
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 123
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 122
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 121
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 120
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 120
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 120
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 119
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 118
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 118
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 118
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 115
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 114
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 112
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 112
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 112
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 112
Surgical treatment of adrenal metastases from non small cell lung cancer 111
Novel inhibitors of pvhl-elongin c binding 111
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 111
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 110
DNA ploidy and S-phase fraction in pulmonary carcinoids. 110
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. 109
Tyrosine kinase inhibitors 109
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 108
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 107
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 106
Prognostic value of 90K protein in HIV infection 105
A Stochastic Model for the HIV/AIDS Dynamic Evolution 105
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 105
Axillary Lymph Node Nanometastases are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients 103
Prognostic value of a novel circulating serum 90K antigen in breast cancer 103
Role of 90K protein in asthma and TH2-type cytokine expression. 103
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 103
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 103
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 102
Tumor-derived microvesicles: The metastasomes. 102
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 100
Unknown primary tumors 100
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 99
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 99
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 99
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 98
Elevated Plasma Levels of 90K (Mac-2 BP) Immunostimulatory Glycoprotein in HIV-1-Infected Children 98
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 98
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 98
Increased levels of soluble P-selectin in hypercholesterolemic patients 97
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 97
[Hairy cell leukemia: prognosis and treatment] 96
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 95
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 95
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 94
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. 94
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 93
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 93
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 93
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 92
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 92
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 91
Combined therapy in pancreatic cancer 91
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 91
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 91
Combinations of biological response modifiers: rationale and clinical responses. 91
A stochastic model for evaluating the HIV anti-retroviral treatment patient cost: a case study 91
Phospholipase Cgamma1 is required for metastasis development and progression 90
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 90
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study. 90
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. 90
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 90
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1 89
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. 89
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 89
Oral etoposide and platinum derivates in the treatment of metastatic Merkel cell carcinoma: report of three cases 89
Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer. 89
Neoadjuvant Chemotherapy for Surgically Staged IIIA N2 Non-Small Cell Lung Cancer (NSCLC) in the Elderly 88
Differential effect on TCR: CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family 88
Totale 11.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.403
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.403
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021676 0 0 0 0 0 229 36 15 59 194 82 61
2021/2022739 11 12 5 137 90 16 15 52 65 14 93 229
2022/20232.806 210 288 173 356 315 597 159 220 329 25 73 61
2023/20241.213 109 37 99 58 67 356 261 39 14 23 16 134
2024/20253.627 200 751 610 90 64 97 124 189 320 186 402 594
2025/20263.129 553 358 707 796 572 143 0 0 0 0 0 0
Totale 18.137